SARS-CoV-2 RBD of Spike protein, K417N, T478K, L452R– lineage B.1.617.2.1 – Indian Delta Plus Variant

Reference:
Product nameSARS-CoV-2 RBD of Spike protein, K417N, T478K, L452R– lineage B.1.617.2.1 – Indian Delta Plus Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
Sequence  YP_009724390.1
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
ApplicationsELISA,WB,,,
Fragment TypeSpike protein fragment
Aliases /Synonymslineage AY.1, lineage AY.2, Delta with K417N, B.1.617.2.1, Indian variant, Delta plus variant
ReferencePX-COV-P062
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

General information on SARS-CoV-2 RBD of Spike protein, K417N, L452R, T478K – AY.1/AY.2 lineage – Indian Delta plus variant

The Delta Plus variant was first identified after routine scanning of genomic variations in the lineage B.1.617.2 (original Delta variant) first reported in India. This new variant, which corresponds to lineages AY.1 and AY.2 (the first more abundant than the second), was shown to carry mutation K417N on its receptor-binding domain (RBD) in addition to mutations L452R and T478K previously reported on the original Delta variant.
The K417N amino acid substitution was previously reported in the Beta variant or lineage B.1.351 first identified in South Africa. This change occurs close to a domain targeted by neutralizing antibodies, for this reason, experts believe it might contribute to an enhanced immune evasion in SARS-CoV-2. This may have a synergistic effect in conjugation with mutation L452R, another substitution that is known to contribute to immune evasion in SARS-CoV-2. In contrast, the T478K mutation occurs within the interface between the RBD and the human receptor ACE2. Several reports indicate that the global prevalence of this amino acid change is slowly increasing hinting at its higher transmissibility and perhaps greater affinity towards the human receptor.
The prevalence of lineage AY.1/AY.2 has been steadily increasing in several European countries including the UK, Switzerland, Portugal, and France, and the United States. More recently, Asian countries including India have reported the first cases of the new Delta plus variant. Although previous reports of the Delta have indicated this variant to be more transmissible and likelier to cause a surge in hospitalizations, it remains to be seen if variant Delta plus will cause similar effects. Given the additional immune-escape-conferring mutation, lineage AY.1 might have a slightly better fitness advantage in comparison to the Delta variant. However, more studies are necessary to understand the concerted effect of the three mutations into SARS-CoV-2 transmissibility, virulence, and ability to evade the immune response generated by different COVID-19 vaccines.

SDS-PAGE for SARS-CoV-2 RBD of Spike protein, K417N, T478K, L452R– lineage B.1.617.2.1 – Indian Delta Plus Variant

SARS-CoV-2 RBD of Spike protein, K417N, T478K, L452R– lineage B.1.617.2.1 – Indian Delta Plus Variant, on SDS-PAGE under non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “SARS-CoV-2 RBD of Spike protein, K417N, T478K, L452R– lineage B.1.617.2.1 – Indian Delta Plus Variant”

Your email address will not be published. Required fields are marked *

Related products

Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1031 400€
Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1032 400€
Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1033 300€
Sotrovimab  Biosimilar – Anti-Spike glycoprotein mAb – Research Grade
Biosimilar Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade PX-TA1637 400€
Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade
Biosimilar Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade PX-TA1750 400€
Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1797 400€
Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1798 400€
Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1799 400€
Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1800 400€
Anti-RBD-4 antibody (Casirivimab)
Biosimilar Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552 300€
Anti-RBD-5 antibody (Imdevimab)
Biosimilar Anti-RBD-5 antibody (Imdevimab) PTXCOV-A553 300€
Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab)
SIL Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552-SIL 1500€
Anti-2019-nCoV(S1) – 2 (H4) antibody
Monoclonal Antibody Anti-2019-nCoV(S1) – 2 (H4) antibody PTXCOV-A514 300€
Anti-2019-nCoV(S1)-1 IgM antibody
Monoclonal Antibody Anti-2019-nCoV(S1)-1 IgM antibody PTXCOV-A542 380€
ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740)
Receptor ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740) PX-COV-P048 185€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.